Argent Biopharma Seeks ASX Quotation for New Shares Issued to Creditor

Argent Biopharma ( (AU:RGT) ) has provided an update.

Argent Biopharma Limited has applied for quotation of 206,000 new fully paid ordinary shares on the ASX, issued to a creditor of the company as part of a previously approved arrangement. The move modestly increases the company’s listed capital base and formalises a creditor settlement structure outlined in its March 2026 meeting documentation, with limited immediate impact on broader operations but incremental implications for existing shareholder dilution and capital management.

The newly issued securities, carrying the ticker RGT, are scheduled to commence quotation from April 10, 2026, following the company’s compliance with ASX listing requirements. While the transaction is relatively small in scale, it underscores Argent Biopharma’s ongoing use of equity-based instruments to manage obligations to creditors and maintain financial flexibility within the constraints of its public listing.

The most recent analyst rating on (AU:RGT) stock is a Sell with a A$0.03 price target. To see the full list of analyst forecasts on Argent Biopharma stock, see the AU:RGT Stock Forecast page.

More about Argent Biopharma

Argent Biopharma Limited is an Australia-listed biotechnology company trading under the ASX code RGT. The company operates in the biopharmaceutical sector, focusing on the development and commercialisation of therapeutic products, with its shares quoted on the Australian Securities Exchange.

Average Trading Volume: 195,442

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$3.03M

See more data about RGT stock on TipRanks’ Stock Analysis page.